Travere Therapeutics, Inc.
Key Metrics
- Previous Close
- $51.10
- 52-Week Range
- $22.59 – $68.73
- Market Cap
- $4.82B
- P/E (TTM)
- —
- EPS (TTM)
- -1.67
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 212.88
- PEG Ratio
- —
- Return on Equity
- -321.22%
- Return on Assets
- -1.84%
- Gross Margin
- 61.07%
- Operating Margin
- -3.13%
- Profit Margin
- -18.66%
- Current Ratio
- 3.00
- Debt/Equity
- 27.28
- Total Debt
- $616.16M
- Free Cash Flow
- $-64.79M
- Revenue Growth
- 36.20%
- Earnings Growth
- —
- Enterprise Value
- $4.97B
Market Snapshot
About
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company has a commercial product for the treatment of IgA nephropathy and a pipeline of investigational therapies. Travere is committed to advancing treatments for patients with high unmet medical needs in rare diseases.